Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer
Status:
Recruiting
Trial end date:
2022-09-17
Target enrollment:
Participant gender:
Summary
Using alternative neoadjuvant gemcitabine-nab-paclitaxel and nal-IRI with 5-Fluorouracil
(5FU) and folinic acid (Leucovorin) regimens of localized cancer, we hope to ensure exposure
of the cancer to a broader array of potentially active agents. Also, potentially improves
patient tolerance and minimizes significant drug toxicity that could impair delivery of all
treatment elements. Furthermore, it may enable prediction of superior to inferior treatment
outcomes at an earlier point in the disease progress.